Granules India Limited (GRANULES) AI Stock Analysis

• Market Cap: ₹127.57B
• Dividend Yield: 0.29%
• Average Volume (3M): 103.28K
• Price to Earnings (P/E): 27.5
• Beta (1Y): 1.21
• Revenue Growth: -4.02%
• EPS Growth: -2.61%
• Country: IN
• Employees: 4,057
• Sector: Healthcare
• Sector Strength: 45
• Industry: Drug Manufacturers - Specialty & Generic
• EPS (TTM): 5.36
• Shares Outstanding: 242,668,720
• 10 Day Avg. Volume: 62,247
• 30 Day Avg. Volume: 103,277
• PEG Ratio: N/A
• Price to Book (P/B): N/A
• Price to Sales (P/S): N/A
• P/FCF Ratio: N/A
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: ₹509.00
• Price Target Upside: -3.18% Downside
• Rating Consensus: Hold
• Number of Analyst Covering: 1

• Rating: 67 Neutral
• Price Target: ₹509.00 ▼(-3.18% Downside)

Granules India Limited's overall stock score is primarily driven by its solid financial performance, characterized by strong profitability and cash generation. Technical analysis indicates potential bearish trends, which slightly dampen the score. The valuation is moderate, with a reasonable P/E ratio but a low dividend yield. The absence of earnings call data and corporate events means these factors do not influence the score.

Granules India Limited Business Overview & Revenue Model

Company Description

Granules India Limited manufactures and sells active pharmaceutical ingredients (APIs), pharmaceutical formulation intermediates, and finished dosages (FDs) in India, North America, Europe, Latin America, Africa, the Middle East, and internationally. The company's APIs in various therapeutic categories include anti-retrovirals, anti-hypertensives, anti-histamines, anti-infectives, analgesics, anti-coagulants, anti-fibriotics, and platelet inhibitors. It also offers various FDs, such as tablets, caplets, and press-fit capsules in bulk, blister packs, and bottles; and other specialty products for oncology. The Company also exports its products. Granules India Limited was founded in 1984 and is based in Hyderabad, India.

How the Company Makes Money

Granules India Limited generates revenue primarily through the sale of its pharmaceutical products, which include APIs, PFIs, and finished dosages. The company has a robust manufacturing infrastructure that allows for the large-scale production of these products, which are then sold to pharmaceutical companies globally. Granules India also engages in contract manufacturing and supply agreements with multinational pharmaceutical companies, further contributing to its revenue streams. The company's earnings are significantly influenced by its ability to maintain quality standards, manage production costs, and expand its market reach through strategic partnerships and global distribution networks.

Granules India Limited Financial Statement Overview

Summary

Granules India Limited demonstrates strong profitability with high gross profit margins and efficient cost management. Though revenue growth has fluctuated slightly, the solid net profit margins and robust cash flow generation indicate a stable financial position. However, the moderately high debt-to-equity ratio suggests some reliance on debt financing.

Income Statement

Granules India Limited shows strong profitability with consistently high gross profit margins. However, revenue growth has seen fluctuations, with a slight decline in the recent year, impacting overall income stability. Net profit margins are solid, indicating efficient cost management.

Balance Sheet

The company maintains a healthy equity base, reflected in a good equity ratio. However, the debt-to-equity ratio is moderately high, indicating reliance on debt financing. Return on equity is strong, showcasing effective use of shareholders' funds for generating profits.

Cash Flow

Granules India Limited exhibits robust operating cash flows, indicating strong cash generation from core operations. Free cash flow has improved significantly, indicating better cash management. The operating cash flow to net income ratio is favorable, highlighting efficient cash utilization.

Breakdown	TTM	Dec 2025	Dec 2023	Dec 2022	Dec 2022	Dec 2021
Income Statement
Total Revenue	44.46B	44.82B	45.06B	45.12B	37.27B	31.96B
Gross Profit	22.67B	18.71B	23.76B	22.05B	17.68B	17.41B
EBITDA	9.61B	9.89B	8.26B	9.28B	7.40B	8.82B
Net Income	4.79B	5.02B	4.05B	5.17B	4.13B	5.49B
Balance Sheet
Total Assets	0.00	62.53B	55.21B	49.05B	45.13B	37.13B
Cash, Cash Equivalents and Short-Term Investments	2.17B	5.96B	3.81B	3.16B	3.96B	2.63B
Total Debt	0.00	14.55B	13.15B	11.36B	11.06B	8.49B
Total Liabilities	-34.27B	25.37B	22.95B	20.70B	19.26B	15.40B
Stockholders Equity	34.27B	37.16B	32.26B	28.35B	25.87B	21.73B
Cash Flow
Free Cash Flow	0.00	1.95B	588.38M	4.52B	-656.53M	1.61B
Operating Cash Flow	0.00	7.67B	4.39B	6.64B	3.32B	4.32B
Investing Cash Flow	0.00	-6.95B	-3.60B	-964.52M	-3.80B	-2.77B
Financing Cash Flow	0.00	109.58M	76.64M	-5.19B	1.90B	-2.99B

Granules India Limited Technical Analysis

• Technical Analysis Sentiment: Positive
• Last Price: 525.70
• 50DMA: Positive
• 100DMA: Positive
• 200DMA: Positive
• MACD: Positive
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For IN:GRANULES, the sentiment is Positive. The current price of 525.7 is above the 20-day moving average (MA) of 518.96, above the 50-day MA of 488.15, and above the 200-day MA of 512.17, indicating a bullish trend. The MACD of 15.20 indicates Positive momentum. The RSI at 57.19 is Neutral, neither overbought nor oversold. The STOCH value of 35.90 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for IN:GRANULES.

Granules India Limited Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
AUROPHARMA	76 Outperform	649.10B	19.15	10.68%	0.36%	7.76%	-2.84%
CIPLA	73 Outperform	1.25T	23.60	16.90%	0.83%	6.40%	25.27%
GRANULES	67 Neutral	₹127.57B	27.46		0.29%	-4.02%	-2.61%
SANOFI	62 Neutral	115.48B	31.99	48.02%	2.34%	-23.93%	-31.53%
APLLTD	60 Neutral	186.73B	31.20	11.24%	1.16%	8.20%	-4.26%
GLENMARK	54 Neutral	568.45B	78.05	11.83%	0.12%	10.99%	0.00%
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%

Granules India Limited Corporate Events

Granules India Limited Announces Change in Registered Office Location

Granules India Limited has announced a change in the location of its registered office, moving from Madhapur to Kondapur in Hyderabad, effective April 21, 2025. This strategic relocation could enhance operational efficiency and reflects the company’s ongoing efforts to optimize its business operations, potentially impacting stakeholders positively.